Eswarco to merge with Jianya, boosting operational scale

Eswarco (1799), a niche generic drug manufacturer in Taiwan, is set to significantly expand its operational scale by integrating its subsidiary Jianya (4130). The share exchange ratio is set at 1 Jianya share for 0.909 Eswarco shares, with tomorrow marking the conversion base date.

Jianya brings substantial assets to the merger, including over NT$1 billion in cash and an annual revenue contribution exceeding NT$400 million. This influx is expected to bolster Eswarco's core business. Eswarco's stock saw a positive reaction, trading up 8.1% to NT$38.65 in early trading on July 27, with 570 shares traded by 10:06 AM.

Eswarco has benefited from strong drug sales in China, reporting a 77.6% year-on-year increase in revenue to NT$463 million in the first half of the year. Analysts predict that the integration of Jianya could help Eswarco's net asset per share surpass NT$10 and enhance its capacity for future mergers and acquisitions.

With a production base in the United States, Eswarco plans to assign some of its product manufacturing to Jianya. This move aims to have Jianya's facilities pass US FDA inspections. Eswarco is also exploring potential contract manufacturing opportunities with another shareholder, Johnson Pharmaceutical (4747), to strengthen the group's overall presence and pursue international collaborations with Taiwanese companies.